Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. reported inducement grants made on February 13, 2026, to ten newly hired employees. These grants included non-statutory stock options for 9,600 shares and restricted stock units (RSUs) for 18,250 shares, issued under the company’s 2021 Inducement Equity Incentive Plan, to attract new talent in accordance with Nasdaq Listing Rule 5635(c)(4). The grants feature four-year vesting schedules, with specific terms for exercise price and vesting commencement dates.
Schrodinger (SDGR) Projected to Post Earnings on Wednesday
Schrodinger (NASDAQ:SDGR) is projected to report its Q4 2025 earnings before market open on Wednesday, February 25, 2026, with analysts expecting a loss of ($0.13) per share. The stock opened at $11.63, below its 50- and 200-day moving averages, and has a market capitalization of approximately $857 million. Wall Street analysts currently hold a "Hold" rating for the stock, with an average price target of $24.33, though opinions vary from "Buy" to "Sell".
Schrodinger (NASDAQ:SDGR) Reaches New 52-Week Low - Should You Sell?
Schrodinger (NASDAQ:SDGR) recently hit a new 52-week low at $11.15, trading well below its moving averages. Analyst ratings are mixed, with an average "Hold" rating and a target price of $24.33, while the company remains unprofitable. Institutional investors hold a significant portion of the stock, which may contribute to its volatility.
Schrodinger Stock Seeks Catalyst Amid Steep Decline ()
Schrodinger (SDGR) stock has experienced a significant decline of nearly 25% since the beginning of 2026, leading investors to eagerly anticipate its upcoming earnings report. The market will be closely watching the company's software segment growth, updates on its drug development pipeline, and 2026 fiscal year guidance to determine if it can reverse the downward trend. Despite the stock's poor performance, analysts maintain an optimistic price target, suggesting a potential recovery if operational metrics align with growth expectations.
Schrodinger (NASDAQ:SDGR) EVP Sells $10,708.80 in Stock
Schrodinger (NASDAQ:SDGR) Executive Vice President Yvonne Tran sold 776 shares of the company's stock on February 10th at an average price of $13.80, totaling $10,708.80. This transaction reduced her stake by 3.28% to 22,859 shares. The sale comes as Schrodinger's stock traded down to $11.31, with analysts having a consensus "Hold" rating and an average price target of $24.33.
Schrodinger (NASDAQ:SDGR) CAO Sells $10,370.08 in Stock
Schrodinger's Chief Accounting Officer, Jenny Herman, sold 752 shares of the company's stock for a total of $10,370.08, reducing her position by 2.75%. Following this transaction, Schrodinger's stock (SDGR) declined by 5.6% mid-day. Despite institutional investors increasing their stakes, the stock has a consensus "Hold" rating from analysts with an average target price of $24.33.
Schrodinger (NASDAQ:SDGR) EVP Sells $12,700.25 in Stock
Schrodinger (NASDAQ:SDGR) EVP Kenneth Patrick Lorton sold 925 shares of the company's stock for $12,700.25 on February 10, 2026, trimming his stake by 1.73%. Following the sale, Lorton directly owns 52,651 shares valued at approximately $722,898. Analysts currently have a "Hold" rating on Schrodinger with an average price target of $24.33.
Schrodinger stock hits 52-week low at 12.8 USD
Schrodinger Inc. (SDGR) stock recently hit a 52-week low of $12.80, reflecting a 44.34% decline over the past year. Despite this downturn, the company maintains a strong balance sheet and InvestingPro analysis suggests the stock is oversold and undervalued. Recent developments include a strategic partnership with Lilly TuneLab and analyst upgrades to "Buy" from firms like BofA Securities and TD Cowen, though UBS initiated coverage with a "Neutral" rating.
Schrodinger stock hits 52-week low at 12.8 USD By Investing.com
Schrodinger Inc. (SDGR) stock reached a 52-week low of $12.80, marking a significant downturn with a 1-year return of -44.34%. Despite this, the company maintains a strong balance sheet and is considered undervalued by InvestingPro, with its next earnings report due on March 4. Schrodinger is also strategically partnering with Lilly TuneLab and focusing on expanding its software platform, leading to varied analyst ratings including upgrades and maintained "Buy" ratings from BofA Securities, TD Cowen, and KeyBanc, while UBS initiated coverage with a "Neutral" rating.
Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25
Schrödinger, Inc. will announce its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after market close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss the results. This event will be accessible via the "Investors" section of Schrödinger's website.
Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25
Schrödinger, Inc. (Nasdaq: SDGR) will release its fourth quarter and full-year 2025 financial results on February 25, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Schrödinger is a computational platform company focused on molecular discovery for drug development and materials design.
Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25
Schrödinger, Inc. (Nasdaq: SDGR) will release its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss these results. Schrödinger, founded in 1990, is a company focused on molecular discovery through its computational platform, used for drug development and materials design by various industries and institutions globally.
Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25
Schrödinger, Inc. (Nasdaq: SDGR) will release its fourth-quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results. The webcast will be accessible in the "Investors" section of their website.
Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Hold" by Brokerages
Schrodinger, Inc. (NASDAQ:SDGR) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $24.33. The company recently surpassed quarterly estimates for EPS and revenue but remains unprofitable, with shares trading near their one-year low. Institutional investors hold approximately 79% of the stock.
Trading Systems Reacting to (SDGR) Volatility
This article analyzes Schrodinger Inc. (NASDAQ: SDGR) volatility using AI models, indicating weak sentiment across all time horizons which supports a short bias. It provides three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss points. The analysis highlights elevated downside risk and presents multi-timeframe signal data for support and resistance levels.
With A 26% Price Drop For Schrödinger, Inc. (NASDAQ:SDGR) You'll Still Get What You Pay For
Schrödinger Inc. (NASDAQ:SDGR) recently experienced a 26% stock price drop over thirty days, adding to a 46% decline over the past year. Despite this, its Price-to-Sales (P/S) ratio of 3.8x remains higher than the Healthcare Services industry average of 2.2x. The elevated P/S ratio is attributed to the company's strong revenue growth (33% last year, 51% over three years) and positive future revenue forecasts, with analysts expecting a 16% annual climb for the next three years, outpacing the industry's 13% forecast.
Schrodinger stock hits 52-week low at 13.43 USD By Investing.com
Schrodinger Inc.'s stock (SDGR) has hit a new 52-week low of $13.43, marking a 43% decrease over the past year, despite the company's strong balance sheet and impressive revenue growth. Analysts have mixed ratings, but some believe the stock may be undervalued and are optimistic about its strategic shift towards software operations and AI-enhanced drug discovery collaborations. Investors are closely monitoring the situation as the stock reaches a critical juncture.
Schrodinger stock hits 52-week low at 13.43 USD
Schrodinger Inc. (SDGR) stock has fallen to a new 52-week low of $13.43, marking a 43% decrease over the past year. Despite this, the company maintains a strong balance sheet and has shown impressive revenue growth, with InvestingPro suggesting the stock may be undervalued and in oversold territory. Schrodinger also recently announced a collaboration with Lilly TuneLab to enhance drug discovery and outlined strategic priorities for fiscal year 2026, receiving mixed analyst ratings.
Schrodinger stock hits 52-week low at 13.43 USD By Investing.com
Schrodinger Inc. (SDGR) stock has fallen to a new 52-week low of $13.43, representing a 43% decrease over the past year. Despite this, the company maintains a strong financial position with more cash than debt and robust revenue growth, and analysts suggest the stock may be undervalued. Recent developments include a collaboration with Lilly TuneLab to enhance drug discovery and a strategic refocus on software operations and preclinical development, leading to mixed but generally optimistic analyst ratings.
Schrodinger (NASDAQ:SDGR) Upgraded at Wall Street Zen
Wall Street Zen has upgraded Schrodinger (NASDAQ:SDGR) from a "sell" to a "hold" rating, contributing to an average "Hold" rating and a $24.33 target price across analysts. Despite beating revenue and EPS estimates last quarter, the company remains unprofitable with a negative net margin. Institutional investors have actively adjusted their stakes in Schrodinger, with a significant portion of the stock owned by hedge funds and other institutional investors.
Schrodinger, Inc. (SDGR) Investor Outlook: Unveiling a 60.98% Potential Upside with Strong Buy Ratings
Schrodinger, Inc. (NASDAQ: SDGR) operates in the health information services industry, leveraging its physics-based computational platform for drug development and materials applications. Despite a recent stock dip and negative performance metrics like EPS and ROE, the company shows significant revenue growth of 53.90% and is in an investment phase, focusing on long-term gains. Analysts maintain a positive outlook with strong buy ratings, forecasting an average target price of $25.00, suggesting a potential 60.98% upside for investors.
Schrodinger Inc stock hits 52-week low at $15.97 By Investing.com
Schrodinger Inc.'s stock has reached a 52-week low of $15.97, reflecting a -32.41% decline over the past year and indicating high volatility. Despite challenges like negative EBITDA and EPS, the company holds more cash than debt, maintains a healthy current ratio, and is considered slightly undervalued with an analyst price target of $32. Schrodinger is also pursuing strategic initiatives including a collaboration with Lilly TuneLab and re-prioritizing its software platform, leading to varied analyst ratings from Buy to Neutral.
Schrodinger Inc stock hits 52-week low at $15.97
Schrodinger Inc. (SDGR) recently hit a 52-week low of $15.97, reflecting a significant year-long decline and higher-than-market volatility. Despite challenges like negative EBITDA and EPS, the company holds more cash than debt, has a healthy current ratio, and analysts see potential for recovery with a high price target of $32. Strategic realignments, including a collaboration with Lilly TuneLab and a focus on software operations, alongside varied analyst ratings, indicate a mixed outlook for the company.
Schrodinger (NASDAQ:SDGR) Hits New 12-Month Low - Should You Sell?
Schrodinger (NASDAQ:SDGR) recently hit a new 52-week low of $15.71, trading down 5.4% with a market capitalization of $1.14 billion. The company reported better-than-expected revenue and EPS for the last quarter but remains unprofitable, with analysts projecting negative EPS for the year. Analyst ratings are mixed, with a consensus "Hold" and an average price target of $24.33, while institutional investors show varied activity.
Schrodinger Inc stock hits 52-week low at $15.97 By Investing.com
Schrodinger Inc.'s stock has hit a 52-week low of $15.97, reflecting a significant downturn with a 32.41% decline over the past year and losses in EBITDA and EPS. Despite these challenges, the company maintains a healthy current ratio, holds more cash than debt, and is considered slightly undervalued, with analysts setting a high price target of $32.00. Recent strategic moves include a collaboration with Lilly TuneLab and a renewed focus on its software operations, leading to varied analyst ratings ranging from Buy to Neutral.
Schrodinger Inc stock hits 52-week low at $15.97 By Investing.com
Schrodinger Inc.'s stock has reached a 52-week low of $15.97, reflecting a significant downturn with a 32.41% decline over the past year and ongoing challenges including negative EBITDA and EPS. Despite high volatility and recent losses, the company holds more cash than debt and maintains a healthy current ratio, with analysts setting a high price target of $32. The company is actively pursuing strategic collaborations, like with Lilly TuneLab, and has seen varied analyst ratings, indicating a period of business model realignment.
How Schrodinger Inc. (SDGR) Affects Rotational Strategy Timing
This article provides an analysis of Schrodinger Inc. (SDGR), highlighting weak sentiment across all horizons and suggesting a short bias. It outlines detailed trading strategies, including long, momentum breakout, and risk hedging, along with specific entry, target, and stop-loss levels. The analysis, generated by AI models, emphasizes risk-reward setups and multi-timeframe signal analysis to aid rotational strategy timing.
Massachusetts Financial Services Co. MA Acquires 577,899 Shares of Schrodinger, Inc. $SDGR
Massachusetts Financial Services Co. MA significantly increased its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 38.7% in the third quarter, acquiring an additional 577,899 shares to own a total of 2,072,433 shares valued at $41.57 million. Despite the company remaining unprofitable with negative margins, it beat analyst estimates for EPS and revenue in its latest quarterly earnings. Schrodinger, a life sciences and materials discovery company, is rated as a "Hold" by analysts with an average price target of $24.33, and institutional investors own 79.05% of its stock.
86,319 Shares in Schrodinger, Inc. $SDGR Acquired by Campbell & CO Investment Adviser LLC
Campbell & CO Investment Adviser LLC has acquired 86,319 shares of Schrodinger, Inc. (NASDAQ:SDGR) valued at approximately $1.73 million, representing a new stake in the company. Other institutional investors like Sumitomo Mitsui Trust Group Inc. and Nikko Asset Management Americas Inc. also increased their positions. Despite institutional interest, analyst sentiment for Schrodinger is cautious, with a consensus "Hold" rating and an average target price of $24.33, alongside mixed recent analyst upgrades and downgrades.
Stephens Investment Management Group LLC Trims Stock Holdings in Schrodinger, Inc. $SDGR
Stephens Investment Management Group LLC reduced its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 3.0% in Q3 2025, selling 68,300 shares and holding approximately 2.98% of the company. Despite beating Q3 EPS and revenue estimates, Schrodinger remains unprofitable with a negative net margin. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $24.33, while the stock trades near its 1-year low.
Schrodinger (NASDAQ:SDGR) Shares Down 5.2% - Time to Sell?
Schrodinger (NASDAQ:SDGR) shares dropped 5.2% on Thursday amidst very low trading volume. Analyst opinions on the company are mixed, with a consensus "Hold" rating and a target price of $24.33, though some firms have lowered targets while Bank of America upgraded the stock to a "Buy." Despite a significant year-over-year revenue increase and an EPS beat last quarter, the company remains unprofitable.
Sumitomo Mitsui Trust Group Inc. Has $91.37 Million Stock Holdings in Schrodinger, Inc. $SDGR
Sumitomo Mitsui Trust Group Inc. increased its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 24.8% in Q3, now owning 4,554,569 shares valued at $91.37 million. Analyst ratings are mixed, with a consensus "Hold" and a price target of $24.33, despite the company reporting better-than-expected revenue and EPS but remaining unprofitable. Insider Margaret Dugan recently sold 1,395 shares, reducing her position by 5.37%.
Schrodinger stock rating reiterated at Buy by TD Cowen on strategic priorities
TD Cowen has reiterated a Buy rating on Schrodinger (NASDAQ:SDGR) with a price target of $24.00, indicating a 29% upside. This follows Schrodinger's announcement of strategic priorities for fiscal year 2026, focusing on clinical program partnerships, software platform expansion, and a renewed emphasis on discovery and preclinical development. The company's Q3 2025 earnings surpassed forecasts, and recent collaborations and analyst upgrades reflect this strategic shift.
(SDGR) and the Role of Price-Sensitive Allocations
This article provides an in-depth AI-driven analysis of Schrodinger Inc. (NASDAQ: SDGR), highlighting a near-term weak sentiment that may signal a resumption of long-term weakness. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, along with multi-timeframe signal analysis and key pricing levels for support and resistance. The report emphasizes an exceptional risk-reward setup targeting a 13.3% gain versus a 0.3% risk.
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities
Schrödinger, Inc. reported its achievements for 2025, emphasizing advancements in its "physics+AI" computational platform and strategic collaborations. The company highlighted new agreements with Lilly and Manas AI, progress in its collaborative and proprietary therapeutic portfolios, and the successful clinical development of several drug candidates. For 2026, Schrödinger plans to further scale its platform, expand into new customer segments, and execute on its therapeutics portfolio, including exploring strategic partnerships for lead clinical programs.
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities
Schrödinger, Inc. updated on its 2025 achievements and outlined its strategic priorities for 2026, focusing on advancing its "physics+AI" computational platform and drug discovery programs. Key 2025 achievements include advancements in toxicology initiatives, the launch of an AI-powered conversational interface, and progress in collaborative and proprietary therapeutic portfolios. For 2026, Schrödinger aims to increase customer adoption, complete clinical data packages for its programs, and explore strategic partnerships to drive continued growth and innovation.
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities
Schrödinger, Inc. (Nasdaq: SDGR) announced its 2026 strategic priorities and reviewed its 2025 achievements, emphasizing its physics+AI computational platform for molecular discovery. Key highlights include new strategic agreements with Lilly and Manas AI, advancements in predictive toxicology, and progress in its collaborative and proprietary drug pipelines, including positive clinical data for SGR-1505 and SGR-3515. The company aims to drive increased customer adoption, expand its offerings, and pursue strategic partnerships for its clinical programs.
Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Hold" from Analysts
Schrodinger, Inc. (NASDAQ:SDGR) has received a consensus "Hold" rating from analysts, with an average one-year target price of $24.33. This follows the company beating Q3 earnings estimates with EPS of -$0.45 and revenue of $54.32M, despite remaining unprofitable with a negative net margin. A key development is Schrodinger's partnership with Eli Lilly, integrating Lilly’s TuneLab AI into its LiveDesign platform, which is expected to boost product value and accelerate revenue growth.
Manas AI Secures Strategic Advantage through Unique Deep Integration with Schrödinger’s Physics + AI Discovery Platform
Manas AI has entered a strategic agreement with Schrödinger, Inc., granting Manas AI extensive access to Schrödinger’s physics-based computational platform. This partnership aims to integrate Schrödinger’s predictive power with Manas AI’s proprietary AI algorithms to accelerate drug discovery timelines and enhance the discovery of novel binders for target proteins. This multi-year agreement emphasizes the convergence of physics and AI in drug discovery.
Chemoinformatics Market to Reach US$ 24.43 Billion by 2033 | CAGR
The global chemoinformatics market is projected to reach US$ 24.43 billion by 2033, growing at a CAGR of 15.1% from US$ 6.91 billion in 2024. This growth is primarily driven by the increasing need for faster, more cost-effective drug discovery through AI-driven platforms, virtual screening, and predictive modeling. Key drivers include the rise of AI/ML in drug discovery, while data security and privacy concerns pose challenges to broader adoption.
Schrödinger partners with Lilly TuneLab to enhance drug discovery By Investing.com
Schrödinger Inc. announced a collaboration with Lilly TuneLab, integrating Schrödinger's LiveDesign platform into TuneLab to accelerate drug discovery through advanced AI capabilities. This partnership will establish LiveDesign as a priority interface for biotech companies within the TuneLab ecosystem, leveraging its enterprise features for various drug design methods. Despite not being profitable, Schrödinger, valued at $1.37 billion, has demonstrated strong revenue growth and maintains a healthy financial position, holding more cash than debt.
Schrödinger partners with Lilly TuneLab to enhance drug discovery
Schrödinger, Inc. announced a collaboration with Lilly TuneLab, an Eli Lilly and Company platform, to accelerate drug discovery using advanced artificial intelligence. The partnership will integrate Lilly TuneLab into Schrödinger’s LiveDesign platform, aiming to expand digital drug design methods for biotech companies. Despite not being profitable, Schrödinger reportedly maintains a strong financial position with significant revenue growth.
Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR?
Schrödinger, Inc. announced a collaboration with Eli Lilly’s TuneLab platform, integrating TuneLab’s AI-driven drug discovery workflows into Schrödinger’s LiveDesign environment. This integration reinforces Schrödinger’s role in AI-driven drug discovery and its "embedded-platform" investment thesis. While offering potential long-term benefits, the near-term investment case still hinges on broader adoption of advanced modules and faces risks from software margin pressure and ongoing losses, despite optimistic revenue forecasts and a significant Novartis collaboration.
Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign
Schrödinger, Inc. announced a collaboration with Eli Lilly and Company to integrate Lilly's TuneLab platform into Schrödinger's LiveDesign informatics platform. This partnership aims to accelerate drug discovery and development by providing biotech companies with access to advanced AI capabilities and workflows within LiveDesign. The collaboration highlights the demand for unified enterprise solutions that democratize access to AI models, physics-based calculations, and experimental data in drug discovery.
Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR?
Schrödinger, Inc. announced a collaboration with Eli Lilly’s TuneLab platform, integrating its AI-driven drug discovery workflows into Schrödinger’s LiveDesign environment. This integration reinforces Schrödinger's thesis of becoming embedded in drug design through its physics-based and AI tools, although near-term changes are limited to broader adoption of advanced modules. The company's investment narrative projects significant revenue and earnings by 2028, with a fair value indicating a 47% upside, despite ongoing risks like margin pressure and potential losses.
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software
Schrodinger (SDGR) will integrate Eli Lilly's (LLY) AI drug discovery platform into its software offerings, as per a Refinitiv report. This collaboration aims to enhance drug discovery capabilities by combining Schrodinger's software with Eli Lilly's artificial intelligence platform. The news highlights a strategic move in the pharmaceutical and technology sectors.
Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign
Schrödinger, Inc. announced a new collaboration with Eli Lilly and Company to integrate Lilly's AI-driven drug discovery platform, TuneLab™, into Schrödinger’s LiveDesign enterprise informatics platform. This partnership aims to accelerate drug discovery and development by making TuneLab workflows accessible to biotech companies through LiveDesign, enhancing collaborative decision-making and democratizing access to advanced computational tools. The collaboration leverages a privacy-first approach using federated learning to ensure data security while facilitating shared innovation.
Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign
Schrödinger, Inc. announced a collaboration with Eli Lilly and Company (Lilly) to integrate Lilly's TuneLab platform into Schrödinger's LiveDesign enterprise informatics platform. This partnership aims to accelerate drug discovery and development by providing biotech companies with access to advanced AI capabilities and computational modeling tools within a unified environment. TuneLab utilizes a privacy-first approach with federated learning, allowing secure collaboration while maintaining data separation.
KeyBanc Maintains Overweight Rating for SDGR but Lowers Price Ta
KeyBanc has reiterated its "Overweight" rating for Schrodinger (SDGR) but has simultaneously lowered its price target from $28.00 to $25.00, representing a 10.71% decrease. This decision by KeyBanc analyst Scott Schoenhaus comes as part of an ongoing assessment of Schrodinger's market position and financial performance, with other analysts also having recently updated their ratings and price targets for the company. Despite the lowered price target, the average target price from 10 analysts for Schrodinger Inc (SDGR) is $25.20, implying an upside of 36.84% from its current price, and the consensus recommendation remains "Outperform."
UBS Initiates Coverage of Schrödinger (SDGR) with Neutral Recommendation
UBS has initiated coverage of Schrödinger (SDGR) with a Neutral recommendation. The average one-year price target for SDGR is $27.77/share, suggesting a potential 47.77% upside from its last closing price of $18.79/share, with projected annual revenue increasing by 131.70%. Institutional ownership remains significant, with key holders like Bill & Melinda Gates Foundation Trust and Rubric Capital Management maintaining substantial positions.
